Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC

• Paola Cravero, MD,
• Nuno Vaz, MD,
• Biagio Ricciuti, MD,
• Sarah E. Clifford, MPH,
• Gianluca DiUbaldi, BS, BA,
• Dawn Drevers, RN,
• Kaitlin Morton, BS,
• Rebecca E. Rivenburgh, BS,
• Mizuki Nishino, MD, MPH,
• Mark M. Awad, MD, PhD

Affiliations

Paola Cravero, MD

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Nuno Vaz, MD

Department of Radiology, Brigham and Women’s Hospital and Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Biagio Ricciuti, MD

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Sarah E. Clifford, MPH

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Gianluca DiUbaldi, BS, BA

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Dawn Drevers, RN

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Kaitlin Morton, BS

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Rebecca E. Rivenburgh, BS

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Mizuki Nishino, MD, MPH

Department of Radiology, Brigham and Women’s Hospital and Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Mark M. Awad, MD, PhD

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; Corresponding author. Address for correspondence: Mark M. Awad, MD, PhD, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115.